SOUTH SAN FRANCISCO, CA, February 26, 2015 – Lyric Pharmaceuticals Inc. today announced the initial closing of a Series A financing round totaling $20.4 million. The financing, co-led by RiverVest Venture Partners, Santé Ventures and Third Point Ventures, includes participation by Aperture Venture Partners.
SAN DIEGO, Feb. 26, 2015 (GLOBE NEWSWIRE) – Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of AuriProTM as a treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement (TTP) surgery.Read More
Cleveland, OH, January 28, 2015– Neuros Medical, Inc., a medical device company, announced it has enrolled the first patients in its pivotal clinical trial to evaluate the Company’s patented Altius® System High Frequency Nerve Block technology for the management of intractable limb pain of amputees.Read More
By: Brian Feldt, Reporter
St. Louis Business Journal
December 26, 2014
RiverVest Venture Partners, the Clayton-based venture capital firm, has for several years been considered one of the leading investing firms in the nation when it comes to medical technology.
This year may be its best campaign yet.
RiverVest exited a dozen portfolio companies since 2011, returning $290.5 million to the firm, or 3.5 times the dollars invested in those companies ($83 million). Read more.
Source: St. Louis Business JournalRead More